THERANEXUS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.05 EUR | -0.47% |
|
-7.89% | -6.25% |
| 12:10pm | Theranexus: share price rises following promising trial results | CF |
| Mar. 11 | Theranexus: CEO takes over as Chairman of the Board | CF |
| Sales 2023 * | - | Sales 2024 * | - | Capitalization | 8.19M 7.68M |
|---|---|---|---|---|---|
| Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 * | - |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-1.05
x | P/E ratio 2024 * |
-
| Employees | 19 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 78.95% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +2.84% | ||
| 1 week | -4.82% | ||
| Current month | -5.82% | ||
| 1 month | +3.53% | ||
| 3 months | +4.53% | ||
| 6 months | -1.54% | ||
| Current year | -3.12% |
1 week
1.04
1.28
1 month
1.001.30
Current year
0.631.35
1 year
0.633.18
3 years
0.6314.98
5 years
0.6323.60
10 years
0.6323.60
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 13-03-18 | |
| Founder | - | 13-03-18 | |
| Director of Finance/CFO | - | 16-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jérôme Martinez
BRD | Director/Board Member | 63 | 18-12-12 |
| Director/Board Member | 50 | 17-09-25 | |
| Founder | - | 13-03-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 1.05 | -0.47% | 141 763 |
| 24-04-18 | 1.055 | -4.09% | 10,551 |
| 24-04-17 | 1.1 | +2.33% | 2,877 |
| 24-04-16 | 1.075 | -2.27% | 1,853 |
| 24-04-15 | 1.1 | -3.51% | 1,614 |
Real-time Euronext Paris, April 19, 2024 at 06:12 am EDT
More quotes
Theranexus is an innovative biopharmaceutical company that emerged from the French Atomic Energy Commission (CEA) and specializes in the treatment of neurological diseases and pioneer in the development of drug candidates targeting both neurons and glial cells.
Theranexus has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.
Calendar
2024-09-24
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.055
EUR
Average target price
4
EUR
Spread / Average Target
+279.15%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.12% | 8.73M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.34% | 21.66B | |
| -18.35% | 20.77B | |
| -8.33% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- ALTHX Stock
